Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Review: outcome of hepatocellular carcinoma in patients with NAFLD

Authors: Chin KM, Prieto M, Cheong CK, et al.
Published in HPB (Oxford) 2021
Background: This systematic review and meta-analysis by KM Chin et al. (Singapore General Hospital, Singapore) aimed to compare the outcomes of curative therapy for hepatocellular carcinoma from NAFLD and non-NAFLD aetiologies. They pooled and examined findings for 5579 patients from 9 studies...
Read MoreReview: outcome of hepatocellular carcinoma in patients with NAFLD

Extrahepatic manifestations of NAFLD: a review

Authors: Wijarnpreecha K, Aby ES, Ahmed A, et al
Published in Clin Mol Hepatol 2020
Diagnosis and management of extrahepatic manifestations of NAFLD are crucial for the treatment of these patients. These manifestations include cardiovascular disease, type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy...
Read MoreExtrahepatic manifestations of NAFLD: a review

Kupffer cells and development of liver fibrosis in NASH

Authors: Kanamori Y, Tanaka M, Itoh M, et al.
Published in iScience 2021
Although recent evidence suggests the involvement of iron accumulation in the pathogenesis of NASH, the underlying mechanisms remain poorly understood. Previously, Y. Kanamori et al. (Nagoya, Japan) reported a unique histological structure termed ‘‘crown-like structure (CLS),’’ where liver-resident macrophages (Kupffer cells) surround...
Read MoreKupffer cells and development of liver fibrosis in NASH

NAFLD: a year in review

Authors: Abdelmalek MF.
Published in Nat Rev Gastroenterol Hepatol 2021
he field of NAFLD and its progressive form, NASH, has, despite the challenges of the COVID-19 pandemic, continued to rapidly evolve in 2020. There have been substantial advances in NAFLD mechanisms, diagnostics, and treatment. Key developments include the identification of a multiparametric cellular and tissue signature to define disease progression...
Read MoreNAFLD: a year in review

Early NASH development: myosteatosis rather than sarcopenia

Authors: Nachit M, De Rudder M, Thissen JP, et al.
Published in J Cachexia Sarcopenia Muscle 2021
A substantial body of literature supports that a low muscle mass, low strength, and/or muscle fatty infiltration (myosteatosis) are associated with NAFLD severity. In order to decipher the kinetics of muscle alterations in relation with liver disease progression, M. Nachit et al. (Institute of Experimental and Clinical Research, UCLouvain, Brussels, Belgium)...
Read MoreEarly NASH development: myosteatosis rather than sarcopenia

Performance of non-invasive tests for the detection of advanced fibrosis in morbidly obese patients

Authors: Alqahtani SA, Golabi P, Paik JM, et al.
Published in Obes Surg 2021
SA Alqahtani et al. remind us of the burden of non-alcoholic fatty liver disease (NAFLD). In the USA, it is the most common cause of chronic liver disease and the prevalence is estimated to be about 25% and will increase in future years. For the management of patients with NAFLD, the determination of the fibrosis is essential. Liver biopsy is the gold standard...
Read MorePerformance of non-invasive tests for the detection of advanced fibrosis in morbidly obese patients

Metabolic drivers of NAFLD

Authors: Bence KK, Birnbaum MJ.
Published in Mol Metab 2020
Significant progress has been made over the past decade in our understanding of NASH pathogenesis, but gaps remain in our mechanistic knowledge of the precise metabolic triggers for disease worsening. Many factors associated with dysregulated systemic metabolism have been implicated in some way with the progression...
Read MoreMetabolic drivers of NAFLD

MAFLD, severe COVID-19 and the gut-liver axis

Authors: Assante G, Williams R, Youngson NA<
Published in J Hepatol 2021
As pointed out by Gabriella Assante et al. (The Institute of Hepatology, Foundation for Liver Research, London, UK), two recent studies in the Journal of Hepatology suggest that MAFLD is a risk factor for progression to severe COVID-19. More studies are required to confirm this. However, it potentially adds MAFLD to a list of risk factors that also includes obesity...
Read MoreMAFLD, severe COVID-19 and the gut-liver axis

Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

Authors: Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, et al.
Published in J Hepatol 2020
Advanced chronic liver disease (ACLD) is a serious public health issue for which a safe and effective treatment is still lacking. It is often associated with portal hypertension and liver fibrosis. Over the recent years, peroxisome proliferator-activated receptors family (PPARs) have been considered as a relevant...
Read MorePan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

Sarcopenia: pathophysiological processes in NAFLD

Authors: Chakravarthy MV, Siddiqui MS, Forsgren MF, et a
Published in Front Endocrinol (Lausanne) 2020
A growing body of evidence places skeletal muscle and the muscle-liver axis at the center of the NAFLD pathogenic cascade. Skeletal muscle is implicated via its impact on insulin resistance and systemic inflammation. Population-based studies suggest that sarcopenia is an effect-modifier across the NAFLD spectrum and is tightly linked...
Read MoreSarcopenia: pathophysiological processes in NAFLD

NAFLD and T2D: A bidirectional relationship

Authors: Muzica CM, Sfarti C, Trifan A, et al.
Published in Can J Gastroenterol Hepatol 2020
NAFLD has been reported to be associated with extrahepatic manifestations such as cardiovascular disease, T2DM, chronic kidney disease, extrahepatic malignancies, endocrine diseases, obstructive sleep apnea, and iron overload. Current data define a more complex relationship between NAFLD and T2DM than was previously believed...
Read MoreNAFLD and T2D: A bidirectional relationship

Extra-hepatic manifestations of NAFLD

Authors: Tariq R, Axley P, Singal AK.
Published in J Clin Exp Hepatol 2020
There is growing evidence to support that NAFLD is a multisystem disease, and it involves extra-hepatic organ systems. Most of the studies have evaluated the association of NAFLD with cardiovascular disease, T2DM, and chronic kidney disease. Studies have also suggested association of NAFLD with colorectal cancer, obstructive sleep apnea, polycystic ovarian...
Read MoreExtra-hepatic manifestations of NAFLD

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES